Search research articles
Contact Us
Filters
Showing results (291-300 of 1,476) with videos related to
Page
of 148
Sort By:
Clinical Neuropharmacology
|
April 1, 1997
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias
F Stocchi, G Nordera, C D Marsden
Expert Opinion on Drug Discovery
|
March 19, 2013
High-throughput structural characterisation of therapeutic protein targets
Brian D Marsden, Michael Sundstrom, Stefan Knapp
British Journal of Pharmacology
|
May 1, 1979
Evidence for metabolite involvement in bromocryptine-induced circling behaviour [proceedings]
P Jenner, C D Marsden, C Reavill
Neurology
|
August 1, 1979
Cortical reflex myoclonus
M Hallett, D Chadwick, C D Marsden
Life Sciences
|
August 7, 1978
An experimental model of tardive dyskinesias
A Clow, P Jenner, C D Marsden
Neuroscience Letters
|
October 24, 1994
GABAergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatment
J Jolkkonen, P Jenner, C D Marsden
British Journal of Pharmacology
|
November 1, 1978
Supersensitivity of cerebral dopamine receptors during on-going chronic (six months) administration of trifluoperazine to rats [proceedings]
A Clow, P Jenner, C D Marsden
The Journal of Pharmacy and Pharmacology
|
October 1, 1982
Are dopamine receptors present on human lymphocytes?
S Fleminger, P Jenner, C D Marsden
The Journal of Pharmacy and Pharmacology
|
August 1, 1993
Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat
S Rose, P Jenner, C D Marsden
The American Journal of Tropical Medicine and Hygiene
|
April 1, 1992
Control of the transmission of Chagas' disease in Mambai, Goias, Brazil (1980-1988)
M T Garcia-Zapata, P D Marsden
Page
of 148
Search research articles
Search
Showing results (291-300 of 1,476) with videos related to
Sort By:
Page
of 148
Clinical Neuropharmacology
|
April 1, 1997
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias
F Stocchi, G Nordera, C D Marsden
Expert Opinion on Drug Discovery
|
March 19, 2013
High-throughput structural characterisation of therapeutic protein targets
Brian D Marsden, Michael Sundstrom, Stefan Knapp
British Journal of Pharmacology
|
May 1, 1979
Evidence for metabolite involvement in bromocryptine-induced circling behaviour [proceedings]
P Jenner, C D Marsden, C Reavill
Neurology
|
August 1, 1979
Cortical reflex myoclonus
M Hallett, D Chadwick, C D Marsden
Life Sciences
|
August 7, 1978
An experimental model of tardive dyskinesias
A Clow, P Jenner, C D Marsden
Neuroscience Letters
|
October 24, 1994
GABAergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatment
J Jolkkonen, P Jenner, C D Marsden
British Journal of Pharmacology
|
November 1, 1978
Supersensitivity of cerebral dopamine receptors during on-going chronic (six months) administration of trifluoperazine to rats [proceedings]
A Clow, P Jenner, C D Marsden
The Journal of Pharmacy and Pharmacology
|
October 1, 1982
Are dopamine receptors present on human lymphocytes?
S Fleminger, P Jenner, C D Marsden
The Journal of Pharmacy and Pharmacology
|
August 1, 1993
Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat
S Rose, P Jenner, C D Marsden
The American Journal of Tropical Medicine and Hygiene
|
April 1, 1992
Control of the transmission of Chagas' disease in Mambai, Goias, Brazil (1980-1988)
M T Garcia-Zapata, P D Marsden
Page
of 148